季节性流感疫苗对实验室确诊流感住院的疫苗有效性——拉丁美洲,2013年
该研究采用病例-检测阴性对照设计,在拉丁美洲9国71家哨点医院纳入2013年全年6月龄至5岁儿童和≥60岁成人严重急性呼吸道感染住院患者,估算三价灭活流感疫苗的有效性。结果显示,完全接种对儿童任何流感相关严重急性呼吸道感染的有效性为47%(95%CI:14-71%),对≥60岁成人为48%(95%CI:34-60%),支持现行疫苗接种策略。
要点
- 完全接种流感疫苗对6月龄至5岁儿童任何流感相关严重急性呼吸道感染的有效性为47%(95%CI:14-71%)。
- 完全接种对≥60岁成人任何流感相关严重急性呼吸道感染的有效性为48%(95%CI:34-60%)。
- 儿童中流感A(H3N2)相关严重急性呼吸道感染的有效性为65%(95%CI:-9;89%),未达统计学显著。
核心结论
- 流感疫苗对完全接种的幼儿和老年人提供了针对严重流感疾病的中等程度保护,支持现行疫苗接种策略。
研究设计与样本
- 采用病例-检测阴性对照设计,估算三价灭活流感疫苗对实验室确诊流感住院的有效性。
- 研究对象为2013年1月至12月在阿根廷、巴西、智利、哥伦比亚、哥斯达黎加、萨尔瓦多、洪都拉斯、巴拿马和巴拉圭71家哨点医院住院的6月龄至5岁儿童和≥60岁成人严重急性呼吸道感染患者。
- 病例为实时逆转录聚合酶链反应(rRT-PCR)确诊流感病毒感染,对照为流感病毒rRT-PCR阴性。
- 采用两阶段随机效应模型估算各目标年龄组的合并疫苗有效性,调整发病月份、年龄和基础疾病。
主要发现
- 共识别2620例严重急性呼吸道感染患者:≤5岁组246例流感病例和720例流感阴性对照,≥60岁组448例病例和1206例对照。
- 参与者中最常见的亚型为流感A(H1N1)pdm09病毒(48%),其次为流感A(H3N2)(34%)和流感B(18%)。
- 儿童中完全接种(既往接种者一剂或未接种者两剂)对任何流感病毒相关严重急性呼吸道感染的调整疫苗有效性为47%(95%CI:14-71%)。
- 儿童中对流感A(H1N1)pdm09相关严重急性呼吸道感染的疫苗有效性为58%(95%CI:16-79%),对流感A(H3N2)相关严重急性呼吸道感染为65%(95%CI:-9;89%)。
- 儿童中对流感B相关严重急性呼吸道感染的完全接种粗疫苗有效性为3%(95%CI:-150;63)。
临床怎么用
- 原文结论支持现行疫苗接种策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite widespread utilization of influenza vaccines, effectiveness (VE) has not been routinely measured in Latin America. METHODS: We used a case test-negative control design to estimate trivalent inactivated influenza VE against laboratory-confirmed influenza among hospitalized children aged 6months-5years and adults aged ≥60years which are age-groups targeted for vaccination. We sought persons with severe acute respiratory infections (SARI), hospitalized at 71 sentinel hospitals in Argentina, Brazil, Chile, Colombia, Costa Rica, El Salvador, Honduras, Panama, and Paraguay during January-December 2013. Cases had an influenza virus infection confirmed by real-time reverse transcription PCR (rRT-PCR); controls had a negative rRT-PCR result for influenza viruses. We used a two-stage random effects model to estimate pooled VE per target age-group, adjusting for the month of illness onset, age and preexisting medical conditions. RESULTS: We identified 2620 SARI patients across sites: 246 influenza cases and 720 influenza-negative controls aged ≤5years and 448 cases and 1206 controls aged ≥60years. The most commonly identified subtype among participants (48%) was the influenza A(H1N1)pdm09 virus followed by influenza A(H3N2) (34%) and influenza B (18%) viruses. Among children, the adjusted VE of full vaccination (one dose for previously vaccinated or two if vaccine naïve) against any influenza virus SARI was 47% (95% confidence interval [CI]: 14-71%); VE was 58% (95% CI: 16-79%) against influenza A(H1N1)pdm09, and 65% (95% CI: -9; 89%) against influenza A(H3N2) viruses associated SARI. Crude VE of full vaccination against influenza B viruses associated SARI among children was 3% (95% CI: -150; 63). Among adults aged ≥60years, adjusted VE against any influenza SARI was 48% (95% CI: 34-60%); VE was 54% (95% CI: 37-69%) against influenza A(H1N1)pdm09, 43% (95% CI: 18-61%) against influenza A(H3N2) and 34% (95% CI: -4; 58%) against B viruses associated SARI. CONCLUSION: Influenza vaccine provided moderate protection against severe influenza illness among fully vaccinated young children and older adults, supporting current vaccination strategies.
引用
- El Omeiri N, Azziz-Baumgartner E, Thompson MG, et al. Seasonal influenza vaccine effectiveness against laboratory-confirmed influenza hospitalizations - Latin America, 2013. Vaccine. 2017. PMID: 28648543. doi:10.1016/j.vaccine.2017.06.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。